Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 244-754-0 | CAS number: 22047-49-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: GLP - Guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
- Report date:
- 1991
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- adopted in 1981
- Deviations:
- yes
- Remarks:
- lack of details on test substance; lack of urinary and ophthalmoscopic examination.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Reference substance 001
- Cas Number:
- 135800-37-2
- Molecular formula:
- C16H32O2 to C26H52O2
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Wilmington, MA, USA.
- Age at study initiation: 6 - 8 weeks old
- Weight at study initiation: 150 - 250 g
- Housing: group housed on hardwood chip bedding.
- Diet: rodent ration, AgWay Prolab, Waverly, NY. USA, ad libitum
- Water: municipal tap water, ad libitum
- Acclimation period: 11 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 ± 3
- Humidity (%): 30-70
- Air changes (per hr): 10-13
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
- The test material was dissolved in vehicle at the following concentrations: 0.025 g/mL, 0.075 g/mL and 0.250 g/mL.
- Dosing volume: 4 mL/kg bw, the doses were adjusted at weekly intervals to maintain a constant dose level by body weight.
VEHICLE
- Justification for use and choice of vehicle: water-insolubility
- Lot/batch no.: CSC-91-01-001VIV - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- once daily, 5 days/week
Doses / concentrations
- Remarks:
- Doses / Concentrations:
100, 300 and 1000 mg/kg bw/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The three dose levels were employed based on the known toxicity of the test material.
Examinations
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION: Yes
- Time schedule for examinations: weekly
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: prior to study initiation and prior to the terminal sacrifice
- Anaesthetic used for blood collection: Yes, carbon dioxide
- Animals fasted: No data
- How many animals: all animals
- Parameters checked: erythrocyte count (RBC), hemoglobin (Hgb), hematocrit (Hct), platelet count (PT), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin conc. (MCHC), mean corpuscular volume (MCV), white blood cell (WBC) differential
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: prior to study initiation and prior to the terminal sacrifice
- Animals fasted: No data
- How many animals: all animals
- Parameters checked: albumin, glucose, LDH, blood urea, ASAT, ALAT, AP, nitrogen (BUN), serum creatinine, total bilirubin, total serum protein, globulin, chloride, phosphorus, potassium, sodium, calcium
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: 1 and 6 hours after dosing and on Days 1, 7, 14, 21 and 28.
Parameters scored: Respiratory, Motor activities, Convulsion, Reflexes, Ocular signs, Cardiovascular signs, Salivation, Piloerection, Analgesia, Muscle tone, Gastrointestinal signs, Skin, Vocalization, Forelimb/Hindlimb grip strength.
The observations for neurotoxicity were made by a technician which was blind with respect to the animals´treatment. The animal to be observed was removed from the cage and placed in a designated area for the neurotoxicological observation. The observations was graded at 1 and 6 h after dosing, and on day 1, 7, 14, 21 and 28 using the following scale: 0 = normal, 1 = mild, 2 = moderate, 3 = severe
ORGAN WEIGHTS:
liver, kidney, adrenals and gonads
DETAILS:
- Hematology/Biochemistry:
Prior to the initiation of the study and prior to the terminal sacrifice, all animals were anesthetized with carbon dioxide and bled for clinical pathological evaluation of the following parameters:
* hematology: erythrocyte count, hemoglobin, hematocrit, platelet count, mean corpuscular volume, mean corpuscular hemoglobin conc., mean corpuscular hemoglobin, WBC differential
* biochemistry: albumin, blood urea, nitrogen, electrolyte (chloride, phosphorus, potassium, sodium, calcium), glucose, serum aspartate aminotransferase, serum alanine aminotransferase, serum creatinine, total bilirubin, total serum protein, globulin, LDH, cholesterol, alkaline phosphatase.
- Procedures during treatment:
Body weight and food consumption were measured weekly. Daily clinical observations included all clinical signs. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, all animals. (Examination of the external surface, all orifices, cranial, thoracic and abdominal cavities)
HISTOPATHOLOGY: Yes, from animals of the control and highest dose group
The following organs were examined histopathologically: adrenal glands, heart, lung, liver, kidney, spleen, ovaries and testes.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
No clinical manifestations were observed during the course of the study in either the control or test animals.
BODY WEIGHT AND WEIGHT GAIN
All animals showed the expected gain in body weigh during the course of the study.
FOOD CONSUMPTION AND COMPOUND INTAKE
There were no significant differences between control and test groups.
HAEMATOLOGY
No treatment-related significant differences were observed. The observed changes had no dose-response.
CLINICAL CHEMISTRY
No treatment-related differences between control and tested groups were observed.
NEUROBEHAVIOUR
No signs of neurotoxicity were observed during the course of the study.
ORGAN WEIGHTS
The relative kidney and liver weights were significantly different in male animals treated with 100 mg/kg compared with control animals.
As the other organs from groups with higher doses showed no significant differences, no dose-response relation occurred. Therefore these changes can be regarded as non-treatment related.
GROSS PATHOLOGY
There were no abnormal signs observed during the gross necropsy of any animal.
HISTOPATHOLOGY: NON-NEOPLASTIC
No treatment-related effects were observed in the analysed organs.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects on: clinical manifestation, neurotoxicity, on various blood parameters (hematology and clinical chemistry), necropsy, organ weights, body weights, food consumption and histopathological findings.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.